Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

NCT00718536 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Addition of raltegravir 800 mg QD to HAART

Sponsor

Germans Trias i Pujol Hospital

Collaborators

[object Object]